

体により認識される 50,000 近辺の蛋白バンド (完全長のパーキン蛋白と考えられる) は, 10 週>20 週>>2 週の順で, 特に 10 週が最大蛋白量を示した. 以上より, 正常ラット脳においてパーキン蛋白は, 脳各部位にほぼ等しく存在しているが, 加齢とともに顕著な量的変動が認められた.

一方, これらの抗血清よりアフィニティー抗体を調製し, ペプチドを標準品としたサンドイッチ型 ELISA 系の作製を試みた結果, Par-M 抗体を用いた ELISA 法により, 最小感度 0.3 ng で 1 ~33 ng/ml を定量できる方法を確認した.

F. 研究発表

[英文原著]

- 1) Nishimura M., Kaji R., Ohta M., Mizuta I., Kuno S. Association Between Dopamine Transporter Gene Polymorphism and Susceptibility to Parkinson's Disease. *Movement Disorders* 17: 831-832
- 2) Ohta K., Ohta M., Mizuta I., Fujinami A., Shimazu S., Sato N., Yoneda F., Hayashi K., Kuno S. The novel catecholaminergic and serotonergic activity enhancer R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane up-regulates neurotrophic factor synthesis in mouse astrocytes, *Neurosci. Lett.* 328 : 205-208 2002
- 3) Mizuta I., Nishimura M., Mizuta E., Yamasaki S., Ohta M., Kuno S. Meta-analysis of alpha synuclein/NACP polymorphism in Parkinson's disease in Japan. *J. Neurol. Neurosurg. Psychiatry* 73 : 350 2002
- 4) Ohta K., Kuno S., Mizuta I., Fujinami A., Matsui H. & Ohta M. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes. *Life Science*, in press.2003

[国内学会発表]

- 1) 榎本亜澄香, 藤波 綾, 松井秀仁, 蛭澤 麻衣, 太田潔江, 久野貞子, 太田光熙. 第 122 回日本薬学会 (2002.3.26-28 千葉) マウス由来アストロサイトにおけるカベルゴリン(CG)及びニセルゴリン(NG)の神経栄養因子産生促進作用
- 2) 久野貞子, 水田依久子, 太田潔江, 太田光熙. 第 43 回日本神経学会 (2002.5.29-31 札幌市). ドパミン D2 作動薬プロモクリプチン, D1D2 作動薬ペルゴリドの培養アストロサイトにおける神経栄養因子刺激作用
- 3) 太田潔江, 太田光熙, 水田郁子, 藤波 綾, 島津誠一郎, 佐藤典幸, 米田文夫, 林 恭三, 久野貞子. 第 75 回日本生化学会 (2002.10.15 京都). The catecholaminergic and serotonergic activity enhancer R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane up-regulates neurotrophic factor synthesis in mouse astrocytes.
- 4) 原宏和, 太田潔江, 久野貞子, 松井秀仁, 藤波 綾, 太田光熙, 足立哲夫. 第 75 回日本生化学会 (2002.10.16 京都). 酸化ストレスにより誘導される SH-SY5Y の細胞死に対するアポモルフィンの保護効果

[国際学会発表]

1. Kuno S, Ohta K, Mizuta I, Fujinami A, Matsui H, Ohta M. International congress of Parkinson's disease and movement disorders. (2002.11.10-14 Florida) Dopamine agonists up-regulate neurotrophic factor synthesis in cultured mouse astrocytes.

研究成果の刊行に関する一覧表

水野美邦

[英文原著]

- 1) Goetz CG, Koller W, Poewe W, Rascol O, Sampaio C, Brin MF, Lees AJ, LeWitt P, Lozano A, Mizuno Y, Nutt J, Oertel W, Olanow E, Tolosa E. Management of Parkinson's Disease; an evidence-based review. *Mov Disord* 2002;17 (Suppl 4):S1-S166
- 2) Hyun DH, Lee M, Hattori N, Kubo S, Mizuno Y, Halliwell B, Jenner P. Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. *J Biol Chem* 2002;277:28572-28577
- 3) Kobayashi H, Krüger R, Markopoulou K, Wszolek Z, Chase B, Taka H, Mineki R, Murayama K, Riess O, Mizuno Y, Hattori N. Haploinsufficiency at the α -synuclein gene underlies phenotypic severity in familial Parkinson's disease. *Brain* 2002 (in press)
- 4) Kobayashi K, Mori H, Okuma Y, Dickson D W, Cookson N, Tsuboi Y, Motoi Y, Tanaka R, Miyashita N, Anno M, Narabayashi H, Mizuno Y. Contrasting genotypes of the tau gene in two phenotypically distinct patients with P301L mutation of frontotemporal dementia and Parkinsonism linked to chromosome 17. *J Neurol* 2002;249:669-675
- 5) Kobayashi T, Ota S, Tanaka K, Ito Y, Hasegawa M, Umeda Y, Motoi Y, Takanashi M, Yasuhara M, Anno M, Mizuno Y, Mori H. A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology *Ann Neurol* 2003;53 (in press)
- 6) Miwa H, Mizuno Y. Enlargements of somatosensory-evoked potentials in progressive supranuclear palsy. *Acta Neurol Scand* 2002;106:209-212
- 7) Miwa H, Kondo T, Mizuno Y. Bell's palsy-induced blepharospasm. *J Neurol* 249 (2002):452-454
- 8) Miwa H, Mizuno Y, Kondo T. Familial hemifacial spasm: report and cases and review of literature. *J Neurol Sci* 2002;193:97-102
- 9) Mori H, Oda M, Komori T, Arai N, Takanashi M, Mizutani T, Hirai S, Mizuno Y. Lewy bodies in progressive supranuclear palsy. *Acta Neuropathol* 2002;104:273-278
- 10) Mori H, Hattori N, Mizuno Y. Genotype-Phenotype Correlation: Familial Parkinson Disease. *Neuropathology* 2003 (in press)
- 11) Ohizumi H, Okuma Y, Fuake J, Fujishima K, Goto K, Mizuno Y. Head tremor in dentatorubral-pallidolusian atrophy. *Acta Neurol Scand* 2002;106:319-321
- 12) Okuma Y, Mizuno Y, Lee RG. Reciprocal Ia inhibition in patients with asymmetric spinal spasticity. *Clin Neurophysiol* 2002;113:292-297
- 13) Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, Ochiishi T, Shimura H, Sharon R, Hattori N, Langston JW, Mizuno Y, Hyman BT, Selkoe DJ, Kosik KS. Parkin localizes to the lewy bodies of Parkinson disease and dementia with lewy bodies. *Am J Pathol* 2002;160:1655-1667
- 14) Suzuki A, Obi K, Urabe T, Hayakawa H, Yamada M, Kaneko S, Onodera, Mizuno Y, Mochizuki H. Feasibility of ex vivo gene therapy for neurological disorders using the new retroviral GCDNsap packaged in the vesicular stomatitis virus G protein. *Journal of Neurochemistry* 2002;82:953-960
- 15) Takanashi M, Mori H, Arima K, Mizuno Y, Hattori N. Expression patterns of tau mRNA isoforms correlate

with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration. *Molecular Brain Research* 2002 (in press)

- 16) Takanashi M, Ohta S, Matsuoka S, Mori H, Mizuno Y. Mixed multiple system atrophy and progressive supranuclear palsy: a clinical and pathological report of one case. *Acta Neuropathol* 2002;103:82-87
- 17) Tanaka R, Mochizuki H, Suzuki A, Katsube N, Ishitani R, Mizuno Y, Urabe T. Induction of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in rat brain after focal ischemia/reperfusion. *J Cereb Blood Flow Metab* 2002;22:280-288
- 18) Tanaka R, Komine-Kobayashi M, Mochizuki H, Yamada M, Furuya T, Migita M, Shimada T, Mizuno Y, Urabe T: Migration of EGFP expressing bone marrow-derived microglia/macrophage into the mice brain following permanent focal ischemia. *Neuroscience* 2003 (in press).
- 19) The Global Parkinson's Disease Survey (GPDS) Steering Committee. Factors Impacting on Quality of Life in Parkinson's Disease. Results from an International Survey. *Mov Disord.* 2002;17:60-67
- 20) Urabe T, Tanaka R, Noda H, Mizuno Y. Anticoagulant Therapy with a Selective Thrombin Inhibitor for Acute Cerebral Infarction: Usefulness of Coagulation Markers for Evaluation of Efficacy. *J Thrombosis* 2002;13:155-160

〔英文著書〕

- 1) Mizuno Y, Hattori N, Shimura H, Kitada T, Kubo S, Wang M, Satpl K, Suzuki T, Chiba T, Tanaka K, Asakawa S, Minoshima S, Shimizu N. Etiology, pathogenesis, and genetics of Parkinson's disease. In *Mapping the Progress of Alzheimer's and Parkinson's Disease*, eds, Mizuno Y, Fisher A, Hanin I, Kluwer Academic / Plenum Publishers, New York, 2002, pp 239-244
- 2) Elibol B, Kobayashi T, Ataç FB, Hattori N, Sahin G, Gürer G, Mizuno Y. Familial Parkinsonism with apathy, depression and central hypoventilation (Perry's syndrome). In *Mapping the Progress of Alzheimer's and Parkinson's Disease*, eds, Mizuno Y, Fisher A, Hanin I, Kluwer Academic / Plenum Publishers, New York, 2002, pp 285-290
- 3) Hattori N, Asakawa S, Shimura H, Kubo S, Sato K, Kitami T, Chikaoka-Kawamura Y, Imai Y, Takahashi R, Suzuki T, Tanaka K, Shimizu N, Mizuno Y. Ubiquitin-proteasome pathway is a key to understanding of nigral degeneration in autosomal recessive juvenile Parkinson's disease. In *Mapping the Progress of Alzheimer's and Parkinson's Disease*, eds, Mizuno Y, Fisher A, Hanin I, Kluwer Academic / Plenum Publishers, New York, 2002, pp 291-296
- 4) Schlossmacher MG, Prosch MP, Gai WP, Sharma N, Medina M, Ochiishi T, Shimura H, Hattori N, Mizuno Y, Hyman BT, Selkoe DJ, Kosik KS. Colocalization of parkin with α -synuclein in the Lewy bodies of Parkinson's disease. In *Mapping the Progress of Alzheimer's and Parkinson's Disease*, eds, Mizuno Y, Fisher A, Hanin I, Kluwer Academic / Plenum Publishers, New York, 2002, pp 297-300
- 5) Shimura H, Schlossmacher MG, Hattori N, Prosch MP, Tockenbacher A, Shneider R, Mizuno Y, Kosik K, Selkoe DJ. Ubiquitination of a novel form of α -synuclein by parkin. In *Mapping the Progress of Alzheimer's and Parkinson's Disease*, eds, Mizuno Y, Fisher A, Hanin I, Kluwer Academic / Plenum Publishers, New York, 2002, pp 301-304
- 6) Mizuno Y, Asakawa S, Suzuki T, Hattori N, Minoshima S, Chiba T, Yoshino H, Shimizu N, Tanaka K. 28. Parkin Mutations (Park2). In *Genetics of Movement Disorders*, ed, Pulst SM, Academic Press, San Diego,

[英文総説]

- 1) Agid Y, Olanow CW, Mizuno Y. Levodopa: why the controversy? *Lancet* 2002;360(9332):575

永津俊治

[英文原著]

- 1) Chen N, Ikemoto K, Sugimoto T, Murata S, Ichinose H, Nagatsu T. A highly sensitive and specific FDCCD method for chirality analysis of naturally occurring pteridines. *Heterocycles* 56: 387-392, 2002
- 2) Kawasaki T, Bekku Y, Suto F, Kitsukawa T, Taniguchi M, Nagatsu I, Nagatsu T, Itoh K, Yagi T, Fujisawa H. Requirement of neuropilin 1-mediated Sema3A signals in patterning of the sympathetic nervous system. *Development* 129: 671-680, 2002
- 3) Ikemoto K, Sugimoto T, Murata S, Tazawa M, Nomura T, Ichinose H, Nagatsu T. (6R)-5,6,7,8-tetrahydro-L-monapterin from *Escherichia coli*, a novel natural unconjugated tetrahydropterin. *Biol Chem* 383: 325-330, 2002
- 4) Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, Kawasaki K, Ono F, Shen Y, Wang L, Mizukami H, Kume A, Matsumura M, Nagatsu I, Urano F, Ichinose H, Nagatsu T, Terao K, Nakano I, Ozawa K. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. *Hum Gene Therapy* 13: 345-354, 2002
- 5) Wang L, Muramatsu S, Lu Y, Ikeguchi K, Fujimoto K, Okada T, Mizukami H, Hanazono Y, Kume A, Urano F, Ichinose H, Nagatsu T, Nakano I, Ozawa K. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. *Gene Therapy* 9: 381-389, 2002
- 6) Ohtsuki M, Shiraishi H, Kato T, Kuroda R, Tazawa M, Sumi-Ichinose C, Tada S, Udagawa Y, Itoh M, Hishida H, Ichinose H, Nagatsu T, Hagino Y, Nomura T. cAMP inhibits cytokine-induced biosynthesis of tetrahydrobiopterin in human umbilical vein endothelial cells. *Life Sci* 70: 2187-2198, 2002
- 7) Suzuki T, Inagaki H, Yamakuni T, Nagatsu T, Ichinose H. Enhanced expression of GTP cyclohydrolase I in V-1-overexpressing PC12D cells. *Biochem Biophys Res Commun* 293: 962-968, 2002
- 8) Nagatsu T. Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy. *J Neural Transm* 109: 731-745, 2002
- 9) Ichino N, Yamada K, Nishii K, Sawada H, Nagatsu T, Ishiguro H. Increase of transcriptional levels of egr-1 and nur77 genes due to both nicotine treatment and withdrawal in pheochromocytoma cells. *J Neural Transm* 109: 1015-1022, 2002
- 10) Nakashima A, Kaneko YS, Mori K, Fujiwara K, Tsugu T, Suzuki T, Nagatsu T, Ota A. The mutation of two amino acid residues in the N-terminus of tyrosine hydroxylase (TH) dramatically enhances the catalytic activity in neuroendocrine AtT-20 cells. *J Neurochem* 82: 202-206, 2002
- 11) Wang LJ, Lu YY, Muramatsu S, Ikeguchi K, Fujimoto K, Okada T, Mizukami H, Matsushita T, Hanazono Y, Kume A, Nagatsu T, Ozawa K, Nakano I. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral

sclerosis. *J Neurosci* 22: 6920-6928, 2002

- 12) Nagatsu T. Amine-related neurotoxins in Parkinson's disease: Past, present, and future. *Neurotoxicology and Teratology* 24: 565-569, 2002
- 13) Ikemoto K, Suzuki T, Ichinose H, Ohye T, Nishimura A, Nishi K, Nagatsu I, Nagatsu T. Localization of sepiapterin reductase in the human brain. *Brain Res* 954: 237-246, 2002
- 14) Lu Y-Y, Wang L-J, Muramatsu S, Ikeguchi K, Fujimoto K, Okada T, Mizukami H, Matsushita T, Hanazono Y, Kume A, Nagatsu T, Ozawa K, Nakano I. Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transcript. *Neurosci Res* 45: 33-40, 2003

[総説]

- 1) Kajita M, Niwa T, Nagatsu T. Tetrahydroisoquinolines (TIQ) and neurodegeneration. In: *Role of Catecholamine Quinone Species in Cellular Toxicity*. Edited by Creveling CR, F. P. Graham Publishing, Johnson City, TN, USA, p. 169-190, 2002
- 2) Nagatsu T, Mogi M, Ichinose H, Togari A. Cytokines and neurotrophins in Parkinson's disease: involvement in apoptosis. In: *Mapping the Progress of Alzheimer's and Parkinson's Disease*. Edited by Mizuno Y, Fisher A, Hanin I, Kluwer Academic/Plenum Publishers, New York, p. 265-270, 2002
- 3) Nagatsu T. Molecular genetics of catecholamines: key molecules bridging basic science with clinical science. In: *Catecholamine Research, From Molecular Insights to Clinical Medicine*. Edited by Nagatsu T, Nabeshima T, McCarty R, Goldstein D. Kluwer Academic/Plenum Publishers, New York, p. 5-17, 2002
- 4) Yamakuni T, Yamamoto T, Yamamoto H, Song SY, Nagatsu T, Kobayashi K, Yokoyama M, Nakano A, Suzuki R, Suzuki N, Iwashita S, Omori A, Ichinose Y, Kato C, Kobayashi M, Ishida Y. Enhancement of noradrenergic phenotype expression in transgenic mice overexpressing V-1, a cytoplasmic ankyrin repeat protein. In: *Catecholamine Research, From Molecular Insights to Clinical Medicine*. Edited by Nagatsu T, Nabeshima T, McCarty R, Goldstein D. Kluwer Academic/Plenum Publishers, New York, p. 53-56, 2002
- 5) Ishiguro H, Yamada K, Sawada H, Nishii K, Sawada M, Goto J, Kanazawa I, Nagatsu T. Dopamine neurons are not affected by expanded polyglutamine stretches in HD gene knock-in mice. In: *Catecholamine Research, From Molecular Insights to Clinical Medicine*. Edited by Nagatsu T, Nabeshima T, McCarty R, Goldstein D. Kluwer Academic/Plenum Publishers, New York, p. 99-102, 2002
- 6) Cubells JF, Zabetian CP, Anderson GM, Price LH, Meyers BS, Malison RT, Nelson JC, Nagatsu T, Ichinose H, Gelernter J. Molecular genetic analysis of plasma dopamine beta-hydroxylase in depression. In: *Catecholamine Research, From Molecular Insights to Clinical Medicine*. Edited by Nagatsu T, Nabeshima T, McCarty R, Goldstein D. Kluwer Academic/Plenum Publishers, New York, p. 423-426, 2002
- 7) Ichinose H, Ichinose CS, Nagatsu T, Nomura T. Dopa-responsive dystonia. In: *Genetics of Movement Disorders*. Edited by Pulst SM. Academic Press/Elsevier Science, Amsterdam, p. 419-428, 2003

小川紀雄

[英文原著]

- 1) Higashi, Y., Asanuma, M., Miyazaki, I., Haque, M.E., Tanaka, K. and Ogawa, N.: The p53-activated gene,

- PAG608, requires a zinc finger domain for nuclear localization and oxidative stress-induced apoptosis. *J. Biol. Chem.*, 277: 42224-42232, 2002.
- 2) Tanaka, K., Fujita, N., Higashi, Y. and Ogawa, N.: Effects of immunophilin ligands on hydrogen peroxide-induced apoptosis in C6 glioma cells. *Synapse*, 43: 219-222, 2002.
 - 3) Tanaka, K., Miyazaki, I., Fujita, N., Yoshioka, M. and Ogawa, N.: GPI1046 prevents dopaminergic dysfunction by activating glutathione system in the mouse striatum. *Neurosci. Lett.*, 321: 45-48, 2002.
 - 4) Tanaka, K., Wada-Tanaka, N., Miyazaki, I., Nomura, M. and Ogawa, N.: Chronic cerebral hyperfusion induces striatal alterations due to the transient increase of NO production and the continuous depression of glutathione content. *Neurochem. Res.*, 27: 331-336, 2002.
 - 5) Yamamoto, N., Kabuto, H., Matsumoto, S., Ogawa, N. and Yokoi, I.: α -Tocopheryl-L-ascorbate-2-o-phosphate diester, a hydroxyl radical scavenger, prevents the occurrence of epileptic foci in a rat model of post-traumatic epilepsy. *Pathophysiology*, 8: 205-214, 2002.
 - 6) Asanuma, M., Miyazaki, I., Higashi, Y., Cadet, J.L. and Ogawa, N.: Methamphetamine-induced increase in striatal p53 DNA-binding activity is attenuated in Cu, Zn-superoxide dismutase transgenic mice. *Neurosci. Lett.*, 325: 191-194, 2002.
 - 7) Asanuma, M., Miyazaki, I., Higashi, Y., Tanaka, K., Haque, M.E., Fujita, N. and Ogawa, N.: Aggravation of 6-hydroxydopamine-induced dopaminergic lesions in metallothionein-I and -II knock-out mouse brain. *Neurosci. Lett.*, 327: 61-65, 2002.
 - 8) Yoshioka, M., Tanaka, K., Miyazaki, K., Fujita, N., Higashi, Y., Asanuma, M. and Ogawa, N.: The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. *Neurosci. Res.*, 43: 259-267, 2002.
 - 9) Miyazaki, I., Asanuma, M., Higashi, Y., Sogawa, A.C., Tanaka, K. and Ogawa, N.: Age-related changes in expression of metallothionein-III in rat brain. *Neurosci. Res.*, 43: 323-333, 2002.
 - 10) Tanaka, K., Fujita, N., Higashi, Y. and Ogawa, N.: Neuroprotective and antioxidant properties of FKBP-binding immunophilin ligands are independent on the FKBP12 pathway in human cells. *Neurosci. Lett.*, 330: 147-150, 2002.
 - 11) Haque, M.E., Asanuma, M., Higashi, Y., Miyazaki, I., Tanaka, K. and Ogawa, N.: Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. *Biochim. Biophys. Acta*, 1619: 39-52, 2003.

[総説]

- 1) Ogawa, N. and Tanaka, K.: Cyclosporin-mediated amelioration of degeneration of dopaminergic neurons in experimental models of parkinsonism. In: (ed.) Borlongan, C.V., Isacson, O. and Sanberg, P.R., *Immunosuppressant Analogs in Neuroprotection*, Humana Press, Totowa, 2002, pp35-48.
- 2) Tanaka, K., Asanuma, M. and Ogawa, N.: Blockade of late-onset reduction of muscarinic acetylcholine receptors by immunosuppressants in forebrain ischemia. In: (ed.) Borlongan, C.V., Isacson, O. and Sanberg, P.R., *Immunosuppressant Analogs in Neuroprotection*, Humana Press, Totowa, 2002, pp215-229.

田中啓二

[英文原著]

- 1) Hendil, K. B., Hartmann-Petersen, R., and Tanaka, K. (2002) 26S proteasomes function as stable entities. *J. Mol. Biol.* 315, 627-636.
- 2) Combaret, L., Tilignac, T., Claustre, A., Voisin, L., Taillandier, D., Obled, C., Tanaka, K., and Attaix, D. (2002) Torbafylline is a powerful inhibitor of enhanced ubiquitin-proteasome-dependent proteolysis in cancer rats. *Biochem. J.* 361, 185-192.
- 3) Unno, M., Mizushima, T., Morimoto, Y., Tomisugi, Y., Tanaka, K., Yasuoka, N., and Tsukihara, T. (2002) The structure of the mammalian 20S proteasome at 2.75 Å resolution. *Structure* 10, 609-618.
- 4) Kadoya, K., Yamamoto, H., Suzuki, T., Yukita, A., Fukui, A., Michine, T., Asahara, T., Tanaka, K., Asashima, N.M., and Kikuchi, A. (2002) Desumoylation activity of Axam, a novel Axin-binding protein, is involved in downregulation of b-catenin. *Mol. Cell. Biol.* 22, 3803-3819.
- 5) Asai, A., Tanahashi, N., Qiu, J.H., Saito, N., Chi, S., Kawahara, N., Tanaka, K., and Kirino T. (2002) Selective proteasomal dysfunction in the hippocampal CA1 region after transient forebrain ischemia. *J. Cereb. Blood. Flow. Metab.* 22, 705-710.
- 6) Yanagawa, Y., Hasezawa, S., Kumagai, F., Fujimuro, M., Naito, T., Makino, T., Yokosawa, H., Tanaka, K., Komamine, A., Hashimoto, J., Sato, T., and Nakagawa, H. (2002) Cell-cycle dependent dynamic change of 26S proteasome distribution in tobacco BY-2 cells. *Plant and Cell Physiol.* 43, 604-613.
- 7) Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, Masuyama N, and Gotoh Y. (2002) Akt enhances Mdm2-mediated ubiquitination and degradation of p53. *J. Biol. Chem.* 277, 21843-21850.
- 8) Yamano, T., Murata, S., Shimbara, N., Tanaka, N., Chiba, T., Tanaka, K. Yui, K., and Udono, H. (2002) Two distinct pathways mediated by PA28 and hsp90 in MHC class I antigen processing. *J. Exp. Med.* 196, 185-196.
- 9) Yoshida, Y., Chiba, T., Tokunaga, T., Kawasaki, H., Iwai, K., Suzuki, T., Ito, Y., Matsuoka, K., Yoshida, M., Tanaka, K., and Tai, T. (2002) E3 ubiquitin-ligase that recognizes sugar chains. *Nature* 418, 438-442.
- 10) Park, K. C., Kim, J. H., Choi, E.-J., Min, S. W., Rhee, S., Baek SH, Chung, S. S., Bang O, Park, D., Chiba, T., Tanaka, K., and Chung, C. H. (2002) Antagonistic regulation of myogenesis by two deubiquitinating enzymes, UBP45 and UBP69. *Proc. Natl. Acad. Sci. USA* 99, 9733-9738.
- 11) Niwa, J., Ishigaki S, Hishikawa N, Yamamoto M, Doyu M, Murata S, Tanaka K, Taniguchi N, Sobue G. (2002) Dornfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity. *J. Biol. Chem.* 277, 36793-36798
- 12) Imai, N., Matsuda, N., Tanaka, K., Nakano, A., Matsumoto, S., and Kang, W. K. (2003) The ubiquitin ligase activities of Bombyx mori nucleopolyhedrovirus RING finger proteins. *J. Virol.* 77, 923-930.
- 13) Sakata, E., Yamaguchi, Y., Kurimoto, E., Kikuchi, J., Yokoyama, S., Yamada, S., Kawahara, H., Yokosawa, H., Hattori, N., Mizuno, Y., Tanaka, K., and Kato, K., (2003) Parkin binds the Rpn10 subunit of 26S proteasomes with the ubiquitin-like domain. *EMBO Rep.* in press.

【総説】

- 1) Tanaka, K., Suzuki, T., Chiba, T., Kitami, T., Machida, Y., Sato, S., Hattori, N., and Mizuno, Y. (2002) Autosomal recessive juvenile parkinsonism and the ubiquitin pathway. *Rec. Adv. Cancer Res.* 205-220 (2002)
- 2) Ogura, T. and Tanaka, K. Dissecting multiple ATP-dependent steps in proteasomal degradation. (2003) *Mol*

Cell 11, 3-5.

- 3) Murata, S., Chiba, T., and Tanaka, K. CHIP : a quality-controlling E3 ligase collaborating with molecular chaperones. *Int. J. Biochem. Cell Biol.* in press.
- 4) Mizuno, Y., Hattori, N., Yoshino, H., Asakawa, S., Minoshima, S., Shimizu, N., Suzuki, T., Chiba, T., and Tanaka K. (2002) Parkin mutations (Park2). In "Genetics of Movement Disorders: Chapter "28. 305-314, Elsevier Sci. (USA)
- 5) Tanaka, K. and Tanahashi, N. (2002) Preparation of proteasomes. in "Cell Biology : A Laboratory Handbook" (Ed. by J. E. Celis) 3rd edition. in press, Academic Press, New York.

久野貞子

[英文原著]

- 1) Nishimura M., Kaji R., Ohta M., Mizuta I., Kuno S. Association Between Dopamine Transporter Gene Polymorphism and Susceptibility to Parkinson's Disease. *Movement Disorders* 17: 831-832
- 2) Ohta K., Ohta M., Mizuta I., Fujinami A., Shimazu S., Sato N., Yoneda F., Hayashi K., Kuno S. The novel catecholaminergic and serotonergic activity enhancer R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane up-regulates neurotrophic factor synthesis in mouse astrocytes, *Neurosci. Lett.* 328 : 205-208 2002
- 3) Mizuta I., Nishimura M., Mizuta E., Yamasaki S., Ohta M., Kuno S. Meta-analysis of alpha synuclein/NACP polymorphism in Parkinson's disease in Japan. *J. Neurol. Neurosurg. Psychiatry* 73 : 350 2002
- 4) Ohta K., Kuno S., Mizuta I., Fujinami A., Matsui H. & Ohta M. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes. *Life Science*, in press.2003

20020884

以降は雑誌/図書に掲載された論文となりますので、
P.41- P.47の「研究成果の刊行に関する一覧表」をご参照ください。